Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Biocartis Group NV
  6. News
  7. Summary
    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biocartis : Disclosure of a transparency notification

09/13/2021 | 11:52am EDT

PRESS RELEASE

REGULATED INFORMATION

13 September 2021, 17:40 CEST

Disclosure of a transparency notification

Mechelen, Belgium, 13 September 2021 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that on 8 September 2021 it received a transparency notification dated 2 September 2021 (the 'Notification') indicating that on that date, the shareholding of Credit Suisse Fund Management S.A., part of Credit Suisse Group AG, crossed below the 3% notification threshold to 2.99%. The Credit Suisse Group AG now holds in aggregate 3.16% of the voting rights in Biocartis, i.e. a decrease of 0.15% compared to the previous transparency notification.

The Notification contains the following information:

  • Reason for the Notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: A parent undertaking or a controlling person.
  • Person subject to the notification requirement: Credit Suisse Group AG, Paradeplatz 8, CH-8001Zürich, Switzerland.
  • Transaction date: 2 September 2021.
  • Threshold that is crossed: 3%.
  • Denominator: 57,545,663.
  • Details of the Notification: Credit Suisse Group AG now holds in aggregate 1,818,193 voting rights.
  • Full chain of controlled undertakings through which the holding is effectively being held: Credit Suisse Group AG, Credit Suisse AG, Credit Suisse AG, Dublin Branch / Credit Suisse Group AG, Credit Suisse AG, Credit Suisse Asset Management International Holding Ltd., Credit Suisse Asset Management & Investor Service (Schweiz) Holding AG, Credit Suisse Fund Management S.A. / Credit Suisse Group AG, Credit Suisse AG, Credit Suisse International.

For further information, reference is made to the Notification which is available hereon the Biocartis website.

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

--- END ---

More information:

Renate Degrave

Head of Corporate Communications & Investor Relations Biocartis

e-mail

rdegrave@biocartis.com

tel

+32

15 631 729

mobile

+32

471 53 60 64

@Biocartis_

www.linkedin.com/Biocartis

1

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result,real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for SARS-CoV-2/flu/RSV and sepsis. More information: www.biocartis.com.Follow us on Twitter: @Biocartis_.

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward- looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

2

Disclaimer

Biocartis Group NV published this content on 13 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2021 15:51:10 UTC.


© Publicnow 2021
All news about BIOCARTIS GROUP NV
10/12BIOCARTIS : Disclosure of a transparency notification
PU
10/12PRESS NEWS BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
09/23BIOCARTIS : Restarts Production Of ML2 Manufacturing Line
MT
09/23BIOCARTIS : Announces Restart of its High-Throughput Cartridge Manufacturing Line
PU
09/23PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Restart of its High-Throughput Cart..
AQ
09/23Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Lin..
CI
09/13BIOCARTIS : Disclosure of a transparency notification
PU
09/13PRESS RELEASE BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
09/02BIOCARTIS : Webcast presentation H1 2021 results
PU
09/02BIOCARTIS : announces H1 2021 results
PU
More news
Financials
Sales 2021 52,9 M 61,4 M 61,4 M
Net income 2021 -81,0 M -94,0 M -94,0 M
Net Debt 2021 106 M 123 M 123 M
P/E ratio 2021 -2,88x
Yield 2021 -
Capitalization 220 M 256 M 256 M
EV / Sales 2021 6,17x
EV / Sales 2022 5,15x
Nbr of Employees 484
Free-Float 86,4%
Chart BIOCARTIS GROUP NV
Duration : Period :
Biocartis Group NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCARTIS GROUP NV
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,83 €
Average target price 6,50 €
Spread / Average Target 69,7%
EPS Revisions
Managers and Directors
Herman Verrelst Chief Executive Officer & Executive Director
Jean-Marc Roelandt Chief Financial Officer
Christian Reinaudo Independent Chairman
Benoit Devogelaere Chief Technology Officer
Piet Houwen Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOCARTIS GROUP NV-17.63%256
MASIMO CORPORATION6.61%15 753
GETINGE AB94.85%11 840
NOVOCURE LIMITED-35.15%11 605
PENUMBRA, INC.53.00%9 794
ASAHI INTECC CO., LTD.-21.70%7 013